Patent US2375152A successfully refreshed from Google Patents.
Patent US4462983A successfully refreshed from Google Patents.
US4462983A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Certain ergot peptide alkaloids administered to the nasal mucosa
Assignee: Novartis AG
•
Filing: 1981-12-08
•
Granted: 1984-07-31
•
Expires: 2001-12-08
Abstract
Abstract The present invention provides a nasal or pulmonary pharmaceutical composition comprising as active agent a compound of formula I, ##STR1## wherein R 1 is hydrogen or halogen, R 2 is hydrogen or alkyl of 1 to 4 carbon atoms, either (i) R 3 is isopropyl, sec-butyl, or isobutyl, R 4 methyl, ethyl or isopropyl and R 5 is hydrogen and R 6 is hydrogen or methoxy or R 5 and R 6 are together a single bond, or (ii) R 3 is benzyl, R 4 is methyl, R 5 is hydrogen and R 6 is hydrogen or methoxy, or (III) dihydroergocristine, in association with a pharmaceutically acceptable carrier or diluent, adapted for nasal or pulmonary administration.
Inventors
- 👤 Moise Azria
- 👤 Thomas Cavanak
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 18:08
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/007; A61K9/0073; A61K9/0075; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/48; A61K9/0043; A61K9/008; A61P; A61P11/00; A61P25/00; A61P25/02; G; G01; G01D; G01D2207/00; G01D2207/10
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
128 words
An improved method of systemically administering a pharmaceutically effective amount of an ergot peptide alkaloid active agent of formula I, ##STR3## wherein R 1 is hydrogen or halogen, R 2 is hydrogen, methyl or isopropyl, either (i) R 3 is isopropyl, sec-butyl or isobutyl, R 4 is methyl, ethyl or isopropyl, and R 5 is hydrogen and R 6 is hydrogen or methoxy or R 5 and R 6 are together a single bond, or (ii) R 3 is benzyl, R 4 is methyl, R 5 is hydrogen and R 6 is hydrogen or methoxy, or (III) dihydroergocristine, or a pharmaceutically acceptable acid addition salt thereof, the improvement which comprises locally administering to the nasal mucous membranes a therapeutically effective amount of the ergot peptide alkaloid active agent.
Claim 2
Dependent Claim
128 words
An improved method of systemically administering a pharmaceutically effective amount of an ergot peptide alkaloid active agent of formula I, ##STR3## wherein R 1 is hydrogen or halogen, R 2 is hydrogen, methyl or isopropyl, either (i) R 3 is isopropyl, sec-butyl or isobutyl, R 4 is methyl, ethyl or isopropyl, and R 5 is hydrogen and R 6 is hydrogen or methoxy or R 5 and R 6 are together a single bond, or (ii) R 3 is benzyl, R 4 is methyl, R 5 is hydrogen and R 6 is hydrogen or methoxy, or (III) dihydroergocristine, or a pharmaceutically acceptable acid addition salt thereof, the improvement which comprises locally administering to the nasal mucous membranes a therapeutically effective amount of the ergot peptide alkaloid active agent.
Claim 3
Dependent Claim
15 words
A method as claimed in claim 1 wherein the compound of formula I is dihydroergotamine.
Claim 4
Dependent Claim
15 words
A method as claimed in claim 1 wherein the compound of formula I is bromocriptine.
Claim 5
Dependent Claim
15 words
A method as claimed in claim 1 wherein the compound of formula I is dihydroergotoxine.
Claim 6
Dependent Claim
21 words
A method as claimed in claim 1 wherein the ergot alkaloid active agent is administered in the form of a spray.
Claim 7
Dependent Claim
16 words
A method as claimed in claim 5 wherein an atomiser containing a propellant produces the spray.
Claim 8
Dependent Claim
14 words
A method as claimed in claim 6 wherein the propellant is a halogenated hydrocarbon.
Claim 9
Dependent Claim
23 words
A method as claimed in claim 5 wherein 0.1 to 5 mg of the ergot peptide alkaloid active agent is administered per administration.
Claim 10
Dependent Claim
14 words
A method as claimed in claim 5 wherein the spray is a powder spray.
Claim 11
Dependent Claim
14 words
A method as claimed in claim 5 wherein the spray is a liquid spray.
Claim 12
Dependent Claim
34 words
A method as claimed in claim 5 wherein the spray is produced from a solution of the ergot peptide alkaloid active agent containing 0.1 to 5 mg of active agent per ml of solution.
Claim 13
Dependent Claim
22 words
A method as claimed in claim 1 wherein the active agent is in the form of a pharmaceutically acceptable acid addition salt.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-31 | 1988-01-30 | 1988-07-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-31 | 1992-01-30 | 1992-07-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-31 | 1996-01-30 | 1996-07-31 | $7700.00 | Window Closed / Lapsed |